ArticleFrontiers in cellular and infection microbiology2021
High Anti-
Article in Frontiers in cellular and infection microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 22 citations in OpenAlex.
- Addressing the Gaps and Challenges of Autochthonous Mucocutaneous Leishmaniasis in Spain.Tropical medicine and infectious disease · 2026Review
- Pilot study evaluating a newly developed nanoparticle-based lateral flow assay for the diagnosis of cutaneous leishmaniasis in Sri Lanka.Tropical medicine and health · 2026Article
- A Human Monoclonal Antibody Targeting α-Gal Ameliorates Experimental Cutaneous Leishmaniasis.The Journal of infectious diseases · 2026Article
- Systemic IgG responses toFrontiers in immunology · 2026Article
- Sex in Immune Cells and Parasitic Diseases - A Complex Relationship.Immunological reviews · 2026Review
- Mice mucosal leishmaniasis model shown high parasite load, increased cytotoxicity and impaired IL-10Frontiers in immunology · 2025Article
- Performance of Extracellular Vesicles FromJournal of parasitology research · 2025Article
- Increased Levels of Anti-Antibodies (Basel, Switzerland) · 2024Article
- Accuracy of serological tests in diagnosing mucosal leishmaniasis.Parasitology research · 2023Article
- Serodiagnosis and therapeutic monitoring of New-World tegumentary leishmaniasis using synthetic type-2 glycoinositolphospholipid-based neoglycoproteins.Emerging microbes & infections · 2022Article
- ELISA-based evaluation of antibody response to Leishmania in a region endemic for cutaneous leishmaniasis.Parasite immunology · 2022Article
- Identification of Immunodominant Antigens From a First-Generation Vaccine Against Cutaneous Leishmaniasis.Frontiers in immunology · 2022Article
- Humoral response in Leishmaniasis.Frontiers in cellular and infection microbiology · 2022Review
- Interleukin-4 Responsive Dendritic Cells Are Dispensable to Host Resistance AgainstFrontiers in immunology · 2021Article
- The Presence ofFrontiers in cellular and infection microbiology · 2021Article
- Treatment failure to sodium stibogluconate in cutaneous leishmaniasis: A challenge to infection control and disease elimination.PloS one · 2021Article
- Immunological biomarkers and their role in the diagnosis and prognosis of leishmaniasis: A case-control study.Tropical parasitologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
Background: Mucosal leishmaniasis (ML), the most inflammatory form of tegumentary leishmaniasis, is predominantly caused by Methods: Patients with a confirmed diagnosis of ML were classified according to clinical staging criteria. Serum levels of Results: Patients in stages IV and V produced higher concentrations of IgG and IgG1 antibodies when compared to those in stage I and II. Significant reductions were seen in the concentrations of IgG and IgG2 antibodies in most patients who responded well to treatment. Conclusions: Our data demonstrate an association between IgG antibody titers and the severity of mucosal disease. The observed reduction in antibody production after successful treatment in most patients preliminarily indicates that these tests can be used to aid in the assessment of therapeutic response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.